What is the CVR number of Neumirna Therapeutics ApS?

Neumirna Therapeutics ApS is registered with CVR / Virk under CVR 41696451.

What is the revenue of Neumirna Therapeutics ApS?

Neumirna Therapeutics ApS reported revenue of DKK -5,5M in 2024.

Neumirna Therapeutics ApS employs 11 people as of the latest annual report.

Ellen Kinson Donnelly is the CEO of Neumirna Therapeutics ApS, in role since 2025.

Luis Garcia Pareras chairs the board of Neumirna Therapeutics ApS, in role since 2025.

Neumirna Therapeutics ApS's registered address is A.C. Meyers Vænge 15.

APSActiveAdvertising protection

CVR 41696451A.C. Meyers Vænge 15, 2450 København SVResearch and experimental development on natural sciences and engineering· NACE 7210Est. 2020 · 5 years old11 employees

Actively employed in the business

Name	Role	Member since
Current (1)
EK Ellen Kinson Donnelly Chief Executive Officer	Chief Executive Officer	2025
Former (1)
JT Janine Terra Erler Chief Executive Officer	Chief Executive Officer	2023 – 2025

Non-executive oversight

Name	Role	Member since
Current (5)
MK Milla Koistinaho Board of Directors	Board of Directors	2023
LG Luis Garcia Pareras Chairman	Chairman	2025
HV Henrik Valdemar Klitgaard Board of Directors	Board of Directors	2020
AW Andreas Wallnöfer Board of Directors	Board of Directors	2025
FP Francesco Paolo Di Giorgio Board of Directors	Board of Directors	2026
Former (6)
MS Markus Sakari Kauppinen Board of Directors	Board of Directors	2020 – 2025
MS Mads Spangaard Rasmussen Chairman	Chairman	2021 – 2022
MP Morten Priskorn Board of Directors	Board of Directors	2020 – 2021
SV Sten Verland Chairman	Chairman	2022 – 2025
LH Lars Hellerung Christiansen Chairman	Chairman	2020 – 2020
TM Thomas Michael Thestrup Board of Directors	Board of Directors	2025 – 2026

As of last annual report

Shareholder	Type	Ownership	Votes	Since
HELLERUNG ApS	Company	25–33.32%	25–33.32%	2025
Innovestor Life Science Fund Ky	Individual	15–19.99%	15–19.99%	2025
Angelini Ventures S.p.A.	Individual	15–19.99%	15–19.99%	2025
INVIVO VENTURES III, FCRE	Individual	10–14.99%	10–14.99%	2025
Wyle Solomon	Individual	5–9.99%	5–9.99%	2020

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.